Get all your news in one place.
100's of premium titles.
One app.
Start reading
StockNews.com
StockNews.com
Business
Mangeet Kaur Bouns

Don't Rule out a Summer Rally for This 1 Biotech Stock

With a $72.55 billion market cap, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis. Its pipeline includes VX-864 for treating AAT deficiency, VX-147 for treating APOL1-mediated focal segmental glomerulosclerosis, VX-880 for treating Type 1 Diabetes, and CTX001 for treating severe SCD and TDT.

The company sells its products primarily to specialty pharmacies and distributors in the United States and specialty distributors, retail chains, hospitals, and clinics internationally.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.